Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-18
    E.g., 2018-11-18

Articles

12389 items
2:07 PM, Nov 05, 2018  |  BC Extra | Financial News

Perceptive doubles up for second debt fund

Perceptive Advisors LLC closed its second debt fund Perceptive Credit Opportunities Fund II at $675 million, above its $500 million target. The figure is twice that of its first debt fund, which closed at $323...
2:47 PM, Nov 02, 2018  |  BC Extra | Financial News

Trump, Xi talks boost Chinese biopharma stocks

Chinese biopharma stocks rose on Friday following trade discussions between President Donald Trump and Chinese President Xi Jinping. On Friday, double-digits gainers included Innovent Biologics Inc. (HKSE:1801), which added HK$1.76 (10%) to HK$18.72; WuXi Biologics Inc....
8:37 AM, Oct 31, 2018  |  BC Extra | Financial News

Orchard achieves $1.2B valuation with $200M IPO

Orchard Therapeutics Ltd. (NASDAQ:ORTX) raised $200 million Wednesday in an IPO that priced at the bottom of its proposed range, but sold more ADSs than proposed. The IPO price values the company at $1.18 billion,...
7:19 AM, Oct 31, 2018  |  BC Extra | Financial News

Innovent shares rise in first day of Hong Kong trading

Innovent Biologics Inc. (HKSE:1801) gained HK$2.60 (19%) to HK$16.58 in its first day of trading Wednesday, delivering the strongest first-day performance yet for a biotech listing on the Hong Kong stock exchange's new biotech chapter. Last...
7:43 AM, Oct 30, 2018  |  BC Extra | Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Monday, hours after...
2:10 AM, Oct 30, 2018  |  BC Extra | Financial News

NASH company Terns raises $80M series B

Terns Pharmaceuticals Inc. (San Mateo, Calif.) will use its untranched $80 million series B funds to advance its acquired clinical and internally discovered preclinical non-alcoholic steatohepatitis assets. The financing was led by new investors Vivo Capital...
11:55 AM, Oct 29, 2018  |  BC Extra | Financial News

Arch to raise $600M for tenth fund

Arch Venture Partners is raising $600 million for its Arch Venture Fund X LP, according to an SEC filing. The firm declined to provide details, although the filing notes that no capital has been raised...
4:20 PM, Oct 26, 2018  |  BC Extra | Financial News

Biotech indexes end tough week on sour note

Biotech indexes fell Friday to finish the week down 6-7%, worse than the broader market. The NASDAQ Biotechnology Index (NBI), SPDR S&P Biotech ETF (XBI) and BioCentury 100 each fell less than 1% Friday, and the...
10:10 AM, Oct 26, 2018  |  BC Extra | Financial News

Gamida Cell raises $50M in NASDAQ IPO

Gamida Cell Ltd. (NASDAQ:GMDA) was up $0.44 to $8.44 Friday after raising $50 million in an IPO in which the Israeli cell therapy company sold more shares than proposed but at a lower price point....
11:02 PM, Oct 25, 2018  |  BC Extra | Financial News

Galecto raises €79M to advance pipeline of galectin inhibitors

Looking to advance several clinical candidates, Galecto Biotech AB (Copenhagen, Denmark) raised €79 million ($91.1 million) in a tranched series C round. Galecto CEO Hans Schambye declined to disclose details regarding the round's tranches. In...

Pages